Table 1.
Summary of patient characteristics by patient group
| Group | All | P value | ||
| Ctrl | IBD | |||
| N (%) | N (%) | N (%) | ||
| Gender | ||||
| Female | 60 (40) | 18 (60) | 78 (43.33) | 0.07 |
| Male | 90 (60) | 12 (40) | 102 (56.67) | |
| Race | ||||
| Black | 19 (12.67) | 1 (3.33) | 20 (11.11) | 0.31 |
| Caucasian | 128 (85.33) | 29 (96.67) | 157 (87.22) | |
| Multiracial | 3 (2) | 0 (0) | 3 (1.67) | |
| Smoking status | ||||
| Former smoker | 83 (55.33) | 16 (53.33) | 99 (55) | >0.99 |
| Never smoked tobacco | 43 (28.67) | 9 (30) | 52 (28.89) | |
| Smokes tobacco daily | 24 (16) | 5 (16.67) | 29 (16.11) | |
| History of other autoimmune disorders | ||||
| No | 124 (82.67) | 23 (76.67) | 147 (81.67) | 0.44 |
| Yes | 26 (17.33) | 7 (23.33) | 33 (18.33) | |
| Small bowel surgery | ||||
| No | 143 (95.33) | 21 (70) | 164 (91.11) | 0.0002 |
| Yes | 7 (4.67) | 9 (30) | 16 (8.89) | |
| Large bowel surgery | ||||
| No | 134 (89.33) | 16 (53.33) | 150 (83.33) | <0.0001 |
| Yes | 16 (10.67) | 14 (46.67) | 30 (16.67) | |
| Cancer stage | ||||
| 2 | 6 (4) | 0 (0) | 6 (3.33) | 0.48 |
| 3 | 12 (8) | 4 (13.33) | 16 (8.89) | |
| 4 | 132 (88) | 26 (86.67) | 158 (87.78) | |
| Cancer type | ||||
| Cancer of bladder | 4 (2.67) | 2 (6.67) | 6 (3.33) | 0.95 |
| Cancer of breast | 6 (4) | 1 (3.33) | 7 (3.89) | |
| Cancer of bronchus; lung | 80 (53.33) | 15 (50) | 95 (52.78) | |
| Cancer of colon | 11 (7.33) | 2 (6.67) | 13 (7.22) | |
| Cancer of head and neck | 5 (3.33) | 1 (3.33) | 6 (3.33) | |
| Cancer of kidney and renal pelvis | 7 (4.67) | 2 (6.67) | 9 (5) | |
| Cancer of other urinary organs | 3 (2) | 1 (3.33) | 4 (2.22) | |
| Cancer of rectum and anus | 3 (2) | 1 (3.33) | 4 (2.22) | |
| Melanomas of skin | 24 (16) | 4 (13.33) | 28 (15.56) | |
| Melanoma of orbit | 7 (4.67) | 1 (3.33) | 8 (4.44) | |
| Cancer treatment | ||||
| Atezolizumab | 22 (14.67) | 5 (16.67) | 27 (15) | 0.996 |
| Atezolizumab, followed by ipilimumab, nivolumab combination | 1 (0.67) | 0 (0) | 1 (0.56) | |
| Durvalumab | 5 (3.33) | 1 (3.33) | 6 (3.33) | |
| Ipilimumab, nivolumab combination | 17 (11.33) | 3 (10) | 20 (11.11) | |
| Ipilimumab, nivolumab combination, followed by pembrolizumab | 4 (2.67) | 1 (3.33) | 5 (2.78) | |
| Nivolumab | 36 (24) | 8 (26.67) | 44 (24.44) | |
| Pembrolizumab | 65 (43.33) | 12 (40) | 77 (42.78) | |
| No of doses, N (median, range) | 6 (1–83) | 6 (1–42) | 6 (1–83) | 0.88 |
| History of chemotherapy | ||||
| No | 52 (34.67) | 10 (33.33) | 62 (34.44) | >0.99 |
| Yes | 98 (65.33) | 20 (66.67) | 118 (65.56) | |
| History of radiation therapy | ||||
| No | 130 (86.67) | 27 (90) | 157 (87.22) | 0.77 |
| Yes | 20 (13.33) | 3 (10) | 23 (12.78) | |
| Prior steroid use | ||||
| No | 19 (12.67) | 5 (16.67) | 24 (13.33) | 0.56 |
| Yes | 131 (87.33) | 25 (83.33) | 156 (86.67) | |
| Age at treatment, years (median, range) | 67 (23–84) | 67 (39–81) | 67 (23–84) | 0.54 |
Patients with IBD and controls were propensity score matched by cancer type, cancer mediation, and age. P values by Fisher’s exact test. Summary of age and number of doses by patient group. P value by Wilcoxon rank-sum test.
IBD, inflammatory bowel disease.